Immobilized Peptide on the Surface of Poly l-DOPA/Silica for Targeted Delivery of 5-Fluorouracil to Breast Tumor
- 7 Downloads
Chemotherapy using drug delivery systems can target tumor cells selectively and do not affect normal cells. In this paper, a specific drug delivery system with immobilized NL2 peptide on the surface of polymeric nano drug was designed for treatment of breast tumor. The tertiary structure of NL2 peptide (AEGEFIHNRYNRFFYWYGDPAK) was selected from the database and synthesized. After that, it was coupled to the synthesized poly 3,4-dihydroxy-l-phenylalanine (DOPA)/SiO2 nano-composite and examined for targeted 5-fluorouracil (5-FU) delivery in nude mice bearing MCF7 human breast carcinoma cells. Investigation of drug deposition in different tissue and in vivo experiments showed drug in combination with functionalized nano-composite with peptide (DPP) improve targeting properties of drug and 5-FU concentration was significantly increased in tumor rather than other tissues. In addition, this functionalization increases antitumor and targeting efficacy than the free 5-FU and non-functionalized nanocomposite.The poly DOPA functionalized peptide is a powerful agent for targeted delivery of anticancer drugs such as 5FU to tumor cells.
Keywords5-Fluorouracil Poly 3,4-dihydroxy-l-phenylalanine Anti-cancer peptide Breast cancer
The authors are grateful for the MCF7 cell line given by the Pasteur Institute of Iran.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
All experiments were performed according to the The International Guiding Principles for Biomedical Research Involving Animals and were approved by the Institutional Bioethics Commission. This investigation does not contain any studies with human participants performed by any of the authors.
- Brahmbhatt H, MacDiarmid J, Engeneic Molecular Deliver Pty Ltd (2018) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells. US Patent Application 15/881,801Google Scholar
- Iturralde D, Spaide R, Meyerle C, Yannuzzi L, Fisher Y, Sorenson J, Slakter J, Klancnik J (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion. Invest Ophthalmol Vis Sci 47:4273–4273Google Scholar
- Saeed AF, Wang R, Ling S, Wang S (2017) Antibody engineering for pursuing a healthier future. Front Microbiol 8:495Google Scholar
- Stewart JM, Soricimed Biopharma Inc (2018) Compounds and methods for the detection of TRPV-6 cancers and drug delivery. US Patent Application 10/064,964Google Scholar
- Tran TN, Pham TVA, Le MLP, Nguyen TPT (2013) Synthesis of amorphous silica and sulfonic acid functionalized silica used as reinforced phase for polymer electrolyte membrane. Adv Nat Sci 4:045007Google Scholar